Short Interest in Tempus AI, Inc. (NASDAQ:TEM) Grows By 20.2%

Tempus AI, Inc. (NASDAQ:TEM) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 6,140,000 shares, a growth of 20.2% from the November 30th total of 5,110,000 shares. Based on an average daily volume of 1,970,000 shares, the short-interest ratio is currently 3.1 days. Currently, 10.5% of the shares of the company are sold short.

Analysts Set New Price Targets

Several research firms have recently commented on TEM. Guggenheim initiated coverage on Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 target price on the stock. Loop Capital upped their price objective on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, October 15th. Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and lifted their target price for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Piper Sandler restated a “neutral” rating and issued a $70.00 price target (up from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Finally, Wolfe Research started coverage on shares of Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $56.00.

Tempus AI Stock Down 3.6 %

TEM stock opened at $33.87 on Tuesday. The company’s 50-day moving average price is $49.76 and its two-hundred day moving average price is $46.89. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI has a 12 month low of $22.89 and a 12 month high of $79.49.

Insider Buying and Selling

In related news, major shareholder Bradley A. Keywell sold 395,800 shares of Tempus AI stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the sale, the insider now owns 16,164,449 shares of the company’s stock, valued at approximately $694,263,084.55. The trade was a 2.39 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Eric P. Lefkofsky sold 187,655 shares of the stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $37.54, for a total transaction of $7,044,568.70. Following the completion of the transaction, the chief executive officer now directly owns 9,557,283 shares in the company, valued at approximately $358,780,403.82. This represents a 1.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 845,041 shares of company stock worth $35,125,473.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. NEA Management Company LLC acquired a new position in Tempus AI during the second quarter worth about $160,048,000. Novo Holdings A S bought a new stake in shares of Tempus AI during the 2nd quarter valued at approximately $142,605,000. Revolution Growth Management Company Inc. bought a new stake in shares of Tempus AI during the 2nd quarter valued at approximately $128,133,000. ARK Investment Management LLC increased its position in Tempus AI by 355.0% during the 3rd quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company’s stock worth $134,604,000 after purchasing an additional 1,855,459 shares in the last quarter. Finally, Alphabet Inc. bought a new position in Tempus AI in the 2nd quarter valued at approximately $54,289,000. 24.22% of the stock is owned by institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.